Paul Tudor Jones's APLS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 650,000 shares of Apellis Pharmaceuticals, Inc. (APLS) worth $26.15 M, representing 0.05% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in APLS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 435,000 shares. Largest reduction occurred in Q4 2021, reducing 150,703 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Apellis Pharmaceuticals (APLS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apellis Pharmaceuticals (APLS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +435,000 | Add 202.33% | 650,000 | $40.23 |
| Q4 2025 | +215,000 | New Buy | 215,000 | $25.12 |
| Q2 2025 | -52,980 | Sold Out | 0 | $0.00 |
| Q1 2025 | +52,980 | New Buy | 52,980 | $21.87 |
| Q4 2024 | -73,002 | Sold Out | 0 | $0.00 |
| Q3 2024 | +73,002 | New Buy | 73,002 | $28.84 |
| Q1 2024 | -9,962 | Sold Out | 0 | $0.00 |
| Q4 2023 | -40,150 | Reduce 80.12% | 9,962 | $59.86 |
| Q3 2023 | +42,714 | Add 577.37% | 50,112 | $38.04 |
| Q2 2023 | +7,398 | New Buy | 7,398 | $91.10 |
| Q3 2022 | -34,707 | Sold Out | 0 | $0.00 |
| Q2 2022 | -14,133 | Reduce 28.94% | 34,707 | $45.21 |
| Q1 2022 | +48,840 | New Buy | 48,840 | $50.82 |
| Q4 2021 | -150,703 | Sold Out | 0 | $0.00 |
| Q3 2021 | +128,065 | Add 565.71% | 150,703 | $32.96 |
| Q2 2021 | +22,638 | New Buy | 22,638 | $63.21 |
| Q1 2021 | -29,448 | Sold Out | 0 | $0.00 |
| Q4 2020 | +9,507 | Add 47.68% | 29,448 | $57.19 |
| Q3 2020 | +19,941 | New Buy | 19,941 | $30.19 |
Paul Tudor Jones's Apellis Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q3 2020, acquiring 19,941 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Apellis Pharmaceuticals, Inc. (APLS) for 19 quarters since Q3 2020.
Paul Tudor Jones's largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q1 2026, adding 650,000 shares worth $26.15 M.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 650,000 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $26.15 M.
As of the Q1 2026 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.05% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 650,000 shares, as reported at the end of Q1 2026.